Pharmacotherapy of obesity: Available medications and drugs under investigation.
Τίτλος | Pharmacotherapy of obesity: Available medications and drugs under investigation. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Pilitsi, E., Farr O. M., Polyzos S. A., Perakakis N., Nolen-Doerr E., Papathanasiou A-E., & Mantzoros C. S. |
Journal | Metabolism |
Volume | 92 |
Pagination | 170-192 |
Date Published | 2019 Mar |
ISSN | 1532-8600 |
Abstract | Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an additional, albeit limited, weight reduction. Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented. |
DOI | 10.1016/j.metabol.2018.10.010 |
Alternate Journal | Metab. Clin. Exp. |
PubMed ID | 30391259 |